Japanese pharmaceutical company Shionogi’s new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September.
From February to July, Shionogi conducted a clinical trial with 1,821 people to evaluate ensitrelvir fumaric acid (S-217622), the oral drug the company developed in February. The subjects were not at risk for other diseases and had been vaccinated.
The endpoint for the clinical trial was the resolution of the five symptoms characteristic of the Omicron virus strain—stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness—according to a statement by the company….